Israel Arango‐Hisijara

Author

Emory University

Also Known As

I ARANGOHISIJARA, I. Arango-Hisijara, I. Arango‐Hisijara, Israel Arango-Hisijara, Israel Arango‐Hisijara

Publications

550

Citations

H-Index

Concepts

All Affiliations

Emory University Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Pharmacyclics (United States)Memorial Sloan Kettering Cancer Center Temple University

About

Israel Arango‐Hisijara is an author at Emory University specializing in extracellular matrix, osteoarthritis, and osteoporosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	140
2	Orthopaedics	1	1	140
3	Physiology	1	1	140
4	Extracellular Matrix	1	1	140
5	Osteoarthritis	1	1	140

Israel Arango‐Hisijara

Publications

532

Citations

H-Index

Page 1

	Year	Citations
Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function Mary F. Barbe, Mario C. Rico, Salih Salihoglu, Experimental Cell Research SclerostinBone Morphogenic ProteinPhysiologyOsteoarthritisOsteoporosis	2008	140
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study Christian Buske, Alessandra Tedeschi, Judith Trotman, Journal of Clinical Oncology	2021	103
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis Ariela Noy, Sven de Vos, Morton Coleman, Blood Advances	2020	94
Osteoactivin acts as downstream mediator of BMP‐2 effects on osteoblast function Samir M. Abdelmagid, Mary F. Barbe, Israel Arango‐Hisijara, Journal of Cellular Physiology	2006	75
Connective tissue growth factor (CTGF/CCN2) is a downstream mediator for TGF‐β1‐induced extracellular matrix production in osteoblasts John A. Arnott, Edem Nuglozeh, Mario C. Rico, Journal of Cellular Physiology	2006	62
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial Judith Trotman, Christian Buske, Alessandra Tedeschi, Clinical Cancer Research	2021	34
Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study Christian Buske, Alessandra Tedeschi, Judith Trotman, Blood	2020	24

Page 1